Department of Surgery, Queen Mary Hospital, Hong Kong, China.
Department of Surgery and State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China.
World J Gastroenterol. 2019 Jul 21;25(27):3563-3571. doi: 10.3748/wjg.v25.i27.3563.
In view of the increasing life expectancy in different parts of the world, a larger proportion of elderly patients with hepatocellular carcinoma (HCC) requiring oncological treatment is expected. The clinicopathological characteristics of HCC in elderly patients and in younger patients are different. Elderly patients, in general, also have more comorbidities. Evaluation of the efficacy of different HCC treatment options in elderly patients is necessary to optimize treatment outcomes for them. Treatment modalities for HCC include hepatectomy, liver transplantation, radiofrequency ablation, transarterial chemoembolization, and molecular-targeted therapy with sorafenib. In this review, current evidence on the risks and outcomes of the different HCC treatments for elderly patients are discussed. According to data in the literature, elderly patients and younger patients benefited similarly from HCC treatments. More clinical data are needed for the determination of selecting criteria on elderly HCC patients to maximize their chance of getting the most appropriate and effective treatments. As such, further studies evaluating the outcomes of different HCC treatment modalities in elderly patients are warranted.
鉴于世界不同地区的预期寿命不断增加，需要接受肿瘤治疗的老年肝细胞癌（HCC）患者的比例预计会更大。老年患者和年轻患者的 HCC 的临床病理特征不同。一般来说，老年患者还患有更多的合并症。评估不同 HCC 治疗方案对老年患者的疗效对于优化他们的治疗结果是必要的。HCC 的治疗方法包括肝切除术、肝移植、射频消融、经动脉化疗栓塞以及索拉非尼的分子靶向治疗。在这篇综述中，讨论了目前关于不同 HCC 治疗方法对老年患者的风险和结果的证据。根据文献中的数据，老年患者和年轻患者从 HCC 治疗中获益相似。需要更多的临床数据来确定老年 HCC 患者的选择标准，以最大限度地提高他们获得最合适和最有效的治疗的机会。因此，有必要进一步研究评估不同 HCC 治疗方法在老年患者中的结果。
